Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Research & Development (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Research & Development for 11 consecutive years, with $15.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 28.38% year-over-year to $15.3 million, compared with a TTM value of $62.3 million through Sep 2025, down 29.21%, and an annual FY2024 reading of $83.4 million, up 7.34% over the prior year.
  • Research & Development was $15.3 million for Q3 2025 at CytomX Therapeutics, up from $13.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $36.6 million in Q4 2021 and bottomed at $13.3 million in Q2 2025.
  • Average Research & Development over 5 years is $22.9 million, with a median of $21.4 million recorded in 2024.
  • Peak annual rise in Research & Development hit 66.22% in 2021, while the deepest fall reached 47.75% in 2021.
  • Year by year, Research & Development stood at $36.6 million in 2021, then tumbled by 46.52% to $19.6 million in 2022, then dropped by 0.91% to $19.4 million in 2023, then fell by 23.71% to $14.8 million in 2024, then rose by 3.47% to $15.3 million in 2025.
  • Business Quant data shows Research & Development for CTMX at $15.3 million in Q3 2025, $13.3 million in Q2 2025, and $18.9 million in Q1 2025.